Immunomedics Announces Updated Results With Sacituzumab

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
26
Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)

Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed)

Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed)

Clinical Benefit Rate at 6 Months = 45% (Locally Assessed)

Submission of Biologics License Application (BLA) for Accelerated Approval of Sacituzumab Govitecan as Third-Line Treatment for mTNBC Remains on Track for First Quarter of 2018

SAN ANTONIO, Dec. 06, 2017 (GLOBE NEWSWIRE) --   Immunomedics, Inc. (NASDAQ: IMMU ) (“Immunomedics” or the “Company”) today announced that a blinded, independent review by an adjudication team of radiologists has determined an ORR of 31%, including six complete responses (CRs) and 28 partial responses (PRs), in 110 patients with mTNBC after receiving treatment with sacituzumab govitecan, the Company’s lead investigational antibody-drug conjugate (ADC), in a Phase 2 study. The independent centrally-reviewed (ICR) median DOR was 9.1 months. These efficacy data are summarized in the table below.

  Blinded ICR* Locally Assessed
ORR 31% (6 CRs, 28 PRs) 34% (3 CRs, 34 PRs)
Median DOR 9.1 months 7.6 months

* Scans from 56 patients with at least 20% tumor reduction based on local assessment were sent for blinded, independent central review. Reviewers were not informed patients had 20% tumor shrinkage or which lesions were target lesions by local reads.

“Given relapsed or refractory mTNBC is currently an unmet clinical need and standard therapies provide a very limited benefit of 10-15% ORR and about 2-3 months progression-free survival, we are very encouraged with the efficacy and safety data sacituzumab govitecan has consistently been showing in this late-stage setting,” commented Aditya Bardia, MD, MPH, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital, Harvard Medical School, Boston, MA, who presented the single-arm study in an oral presentation during the 2017 San Antonio Breast Cancer Symposium.

Michael Pehl, President and Chief Executive Officer-elect of Immunomedics, stated, “We believe the blinded independent adjudication affirms the significant clinical activity of sacituzumab govitecan as a single agent in the third-line setting for patients with relapsed or refractory mTNBC. We remain focused on bringing this important medicine to breast cancer patients expeditiously and on transforming Immunomedics into a fully integrated biopharmaceutical company, creating value for our stockholders. To that end, the completion of this Phase 2 study is the second major step in our preparation of a BLA to be submitted to the FDA for accelerated approval of sacituzumab govitecan in this very aggressive form of cancer.”

In addition to a robust median duration of response, nine responders were progression free for more than one year from start of sacituzumab govitecan treatment, four of which were longer than two years. As of data cutoff on June 30, 2017, twelve responding patients were still receiving sacituzumab govitecan.

Overall, patients benefit from sacituzumab govitecan treatment irrespective of age, onset of metastatic disease, or number of prior regimens. Most patients spent more time on sacituzumab govitecan treatment compared to the time spent on last prior therapy. These include 19 patients with prior checkpoint inhibitor therapies who reported an encouraging ORR of 47% (9 of 19) with sacituzumab govitecan. The table below summarizes the ORR of various subgroups.

Subgroups ORR
Age <55 37% (20/54)
  > 55 30% (17/56)
Onset of metastatic disease <1.5 years 29% (16/55)
  > 1.5 years 38% (21/55)
Prior regimens for metastatic disease 3 rd line 36% (16/45)
  > 4 th line 32% (21/65)
Visceral Involvement at study entry Yes 30% (26/88)
  No 50% (11/22)
Trop-2 IHC (N = 62) 0-1 (weak, absent) 0% (0/5)
  2-3 (moderate, strong) 40% (23/57)
No Trop-2 IHC 29% (14/48)
Prior checkpoint inhibitors 47% (9/19)

These encouraging results will be part of a BLA package anticipated to be submitted in the first quarter of 2018 to the FDA for accelerated approval of sacituzumab govitecan as a third-line treatment for patients with mTNBC.

Sacituzumab govitecan has a predictable and manageable safety profile. Grade 3 or 4 adverse events with more than 5% frequency include neutropenia (41%), leukopenia (14%), anemia (10%), diarrhea (8%), and febrile neutropenia (7%).  Side effects were managed with supportive medication or dose modifications. There were no treatment-related deaths.

Investor Event At 8:00 pm Central Time today, Wednesday, December 6, 2017, Immunomedics will host an investor event at The Grand Hyatt, Room Republic B, San Antonio, TX. Leading the discussion on the current treatment landscape for mTNBC will be Harold J. Burstein, MD, PhD, Associate Professor of Medicine at Harvard Medical School, and medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Linda T. Vahdat, MD, MBA, medical oncologist at Memorial Sloan Kettering Cancer Center and Chief of Medical Oncology and Clinical Director of Cancer Services at Norwalk Hospital will review the Phase 2 results with sacituzumab govitecan in mTNBC. Michael Pehl, President and Chief Executive Officer-elect of Immunomedics will also be present to provide the Company’s strategic priorities. Audio and slides will be webcast live at https://immunomedics.com/investors/ . Approximately two hours following the live event, a webcast replay will be available on the Company’s website for approximately 30 days.

About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ most advanced product candidate is sacituzumab govitecan (IMMU-132), an antibody-drug conjugate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with metastatic triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics’ primary goal is to bring sacituzumab govitecan to market for the benefit of patients and the creation of stockholder value. For additional information on the Company, please visit its website at https://immunomedics.com/ . The information on its website does not, however, form a part of this press release.

Cautionary note regarding forward-looking statements This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out-licensing arrangements, forecasts of future operating results, potential collaborations, and capital raising activities, timing for bringing any product candidate to market, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.  

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 ccheng@immunomedics.com

Media/Investor Contact: Dan Zacchei / Josh Hochberg Sloane & Company 212-486-9500 Dzacchei@sloanepr.com Jhochberg@sloanepr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 105

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Sophia Space Tests the Software Layer for Orbit Ahead

Updated Category News Views 37

Orbit got a little less theoretical when Sophia Space put its operating system across multiple Kepler Communications satellites. That is not a finished orbital data center, despite the inevitable big-language parade around this sort of announcement. It is a software deployment, a real one, aboard Kepler's Tranche 1 optical data relay constellation. In an industry stuffed...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 6

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 167

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 77

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 28

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 83

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading

Top 5 Most Recently Viewed Articles

Radius Insights Launches New Technology Research Practice

Updated Category News Views 131

Radius Insights Launches Radius Tech A focused expansion of Radius' technology expertise aims to help tech brands make smarter, faster growth decisions. Radius Insights recently unveiled the launch of Radius Tech, a dedicated technology division within Radius designed to deliver precise market research and customer insights specifically tailored for technology companies....

Continue Reading
Urgent Reminder for WM Technology Shareholders on Lead Plaintiff Deadline

Updated Category News Views 176

Important Information for WM Technology Shareholders The Gross Law Firm is reaching out to shareholders of WM Technology, Inc. (NASDAQ: MAPS). This notice serves as a crucial reminder regarding the upcoming deadline for appointing a lead plaintiff in the class action lawsuit involving the company. Who Should Contact the Gross Law Firm? If you have purchased shares of MAPS...

Continue Reading
Gaxos.ai to Skyrocket Connections at Unite 2024 Conference

Updated Category News Views 71

Gaxos.ai's Involvement at Unite 2024 Conference Gaxos.ai Inc. is preparing for a major presence at the Unite 2024 Conference, a vibrant event dedicated to showcasing the latest innovations in gaming and technology. This conference is well-known for bringing together game developers, artists, and tech enthusiasts. Running from September 18 to September 20, Gaxos is eager...

Continue Reading
XNRGY Climate Systems Completes Strategic Growth Financing

Updated Category News Views 365

XNRGY Climate Systems Strengthens Financial Foundation XNRGY Climate Systems, recognized as a key player in sustainable technologies, recently revealed that it has effectively finalized its financing round. This includes a significant investment partnership with Capital Bridge Group and Prologis Ventures. With this move, XNRGY aims to push forward its mission of advancing...

Continue Reading
BioLife Solutions Sells SAVSU to Enhance Logistics Strategy

Updated Category News Views 211

BioLife Solutions Completes Strategic Sale of SAVSU BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent provider of cell processing tools for the cell and gene therapy market, has recently announced a significant event in its operational strategy. The company has sold its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC., previously known as...

Continue Reading